Antistaphylococcal activity of oritavancin and its synergistic effect in combination with other antimicrobial agents

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 10, 2014, Pages 6251-6254

  Lin, Gengrong ^a   Pankuch, Glenn ^a   Appelbaum, Peter C ^a   Kosowska Shick, Klaudia ^a,b  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b Eurofins Medinet Inc   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; DAPTOMYCIN; GENTAMICIN; LINEZOLID; MINOCYCLINE; ORITAVANCIN; RIFAMPICIN; ANTIINFECTIVE AGENT; GLYCOPEPTIDE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL VIABILITY; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL COMMUNITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; DRUG SYNERGISM; GLYCOPEPTIDES; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS;

EID: 84907260952     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02932-14     Document Type: Article

References (20)

1. Kosowska-Shick K, Ednie LM, McGhee P, Smith K, Todd CD, Wehler A, Appelbaum PC. 2008. Incidence and characteristics of vancomycin nonsusceptible strains of methicillin-resistant Staphylococcus aureus at Hershey Medical Center. Antimicrob. Agents Chemother. 52:4510-4513. http://dx.doi.org/10.1128/AAC.01073-08.
2. BEI Resources. 2014. Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA). http://www.narsa.net/control/member/allapprovedisolates.
3. Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML. 2010. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin. Microbiol. Rev. 23:99-139. http://dx.doi.org/10.1128/CMR .00042-09.
4. Credito K, Lin G, Appelbaum PC. 2007. Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology. Antimicrob. Agents Chemother. 51:1504-1507. http://dx.doi.org/10.1128/AAC.01455-06.
5. Julian K, Kosowska-Shick K, Whitener C, Roos M, Labischinski H, Rubio A, Parent L, Ednie L, Koeth L, Bogdanovich T, Appelbaum PC. 2007. Characterization of a daptomycin-nonsusceptible vancomycinintermediate Staphylococcus aureus strain in a patient with endocarditis. Antimicrob. Agents Chemother. 51:3445-3448. http://dx.doi.org/10.1128/AAC.00559-07.
6. Arhin FF, Draghi DC, Pillar CM, Parr TR, Jr, Moeck G, Sahm DF. 2009. Comparative in vitro activity profile of oritavancin against recent grampositive clinical isolates. Antimicrob. Agents Chemother. 53:4762-4771. http://dx.doi.org/10.1128/AAC.00952-09.
7. Arhin FF, Kurepina N, Sarmiento I, Parr TR, Jr, Moeck G, Kreiswirth B. 2010. Comparative in vitro activity of oritavancin against recent, genetically diverse, community-associated methicillin-resistant Staphylococcus aureus (MRSA) isolates. Int. J. Antimicrob. Agents 35:93-94. http://dx.doi .org/10.1016/j.ijantimicag.2009.07.012.
8. Belley A, Neesham-Grenon E, Arhin FF, McKay GA, Parr TR, Jr, Moeck G. 2008. Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus. Antimicrob. Agents Chemother. 52:3820-3822. http://dx.doi.org/10.1128/AAC.00361-08.
9. Lin G, Pankuch GA, Ednie LM, Appelbaum PC. 2010. Antistaphylococcal activities of telavancin tested alone and in combination by time-kill assay. Antimicrob. Agents Chemother. 54:2201-2205. http://dx.doi.org/10.1128/AAC.01143-09.
10. National Committee for Clinical Laboratory Standards. 1999. Methods for determining bactericidal activity of antimicrobial agents. Approved guideline M26. NCCLS, Wayne, PA.
11. Arhin FF, Belley A, McKay GA, Moeck G. 2010. Characterization of the in vitro activity of novel lipoglycopeptide antibiotics. Curr. Protoc. Microbiol. Chapter 17:Unit 17.1. http://dx.doi.org/10.1002/9780471729259 .mc1701s16.
12. American Society for Microbiology. 2014. Instructions to authors. American Society for Microbiology, Washington, DC.
13. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M07-A9. Ninth ed. Clinical and Laboratory Standards Institute, Wayne, PA.
14. Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing. Approved standard M100-S22. Twenty-second informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
15. Kaatz GW, Lundstrom TS, Seo SM. 2006. Mechanisms of daptomycin resistance in Staphylococcus aureus. Int. J. Antimicrob. Agents 28:280-287. http://dx.doi.org/10.1016/j.ijantimicag.2006.05.030.
16. McKay GA, Beaulieu S, Arhin FF, Belley A, Sarmiento I, Parr T, Jr, Moeck G. 2009. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. J. Antimicrob. Chemother. 63:1191-1199. http://dx.doi.org/10 .1093/jac/dkp126.
17. Belley A, Arhin FF, Sarmiento I, Deng H, Rose W, Moeck G. 2013. Pharmacodynamics of a simulated single 1200 mg dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillinresistant Staphylococcus aureus infection. Antimicrob. Agents Chemother. 57:205-211. http://dx.doi.org/10.1128/AAC.01428-12.
18. Ambrose PG, Drusano GL, Craig WA. 2012. In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans. Clin. Infect. Dis. 54(Suppl 3):S220-S228. http://dx.doi.org/10 .1093/cid/cis001.
19. Saravolatz LD, Pawlak J, Johnson LB. 2010. In vitro activity of oritavancin against community-associated meticillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin- resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA). Int. J. Antimicrob. Agents 36:69-72. http://dx.doi.org/10.1016/j.ijantimicag.2010.02.023.
20. Arhin FF, Sarmiento I, Parr, TR, Jr, Moeck G. 2009. Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin. J. Antimicrob. Chemother. 64:868-870. http://dx.doi.org/10.1093/jac/dkp286.